TY - JOUR
T1 - Long-term Disease Course of Crohn’s Disease in a Prospective European Population-based Inception Cohort
T2 - An Epi-IBD Cohort Study
AU - Wewer, Mads Damsgaard
AU - Lophaven, Søren
AU - Lakatos, Peter L.
AU - Gonczi, Lorant
AU - Salupere, Riina
AU - Kievit, Hendrika Adriana Linda
AU - Nielsen, Kári Rubek
AU - Midjord, Jóngerð
AU - Domislovic, Viktor
AU - Krznarić, Željko
AU - Pedersen, Natalia
AU - Kjeldsen, Jens
AU - Halfvarson, Jonas
AU - Sebastian, Shaji
AU - Goldis, Adrian
AU - Arebi, Naila
AU - Oksanen, Pia
AU - Neumann, Anders
AU - Andersen, Vibeke
AU - Katsanos, Konstantinos H.
AU - Koukoudis, Anastasios
AU - Turcan, Svetlana
AU - Ellul, Pierre
AU - Kupcinskas, Juozas
AU - Kiudelis, Gediminas
AU - Fumery, Mathurin
AU - Kaimakliotis, Ioannis P.
AU - D’Inca, Renata
AU - Lombardini, Silvia
AU - Hernandez, Vicent
AU - Fernandez, Alberto
AU - Langholz, Ebbe
AU - Munkholm, Pia
AU - Burisch, Johan
PY - 2026/6
Y1 - 2026/6
N2 - Background & Aims The Epi-IBD cohort is a population-based inception cohort of patients with inflammatory bowel disease from 22 European centers. The aim was to assess the 10-year disease course of patients with Crohn’s disease (CD) and how regional differences in treatment strategies impact the disease course. Methods Patients were followed prospectively from the time of diagnosis, with uniform collection data. Associations between outcomes and covariates were analyzed by multivariable Cox regressions in a propensity score-matched sub-population to address time to first intestinal resection. Results A total of 547 patients with CD were recruited (Eastern Europe: 139 [25.4%]; Western Europe: 408 [74.6%]). Ten-year cumulative rate of advanced therapy use was higher in Western (42%) compared with Eastern Europe (27%) ( P < .05). The median period until initiation of advanced treatment was shorter in Western Europe (10 vs 46 months; P < .001). Despite these differences, the need for surgery remained comparable in Eastern and Western Europe, with a 10-year rate of 24% ( P = .9). A similar comparability was observed for disease progression from uncomplicated disease to complicated disease (10-year rate: 20%; P = .07) and hospitalization (10-year rate: 41%; P = .5). Use of advanced therapy, stricturing or penetrating disease at diagnosis, progression of disease behavior, and former smoking were all associated with an increased risk of intestinal resection (all P < .05). Conclusions Despite earlier and more frequent use of advanced therapies in Western Europe, no differences in disease outcomes were observed between Western and Eastern European patients. Ten years after diagnosis, 1 in 5 patients with uncomplicated disease at diagnosis progressed to complicated disease, and 1 in 4 needed surgery.
AB - Background & Aims The Epi-IBD cohort is a population-based inception cohort of patients with inflammatory bowel disease from 22 European centers. The aim was to assess the 10-year disease course of patients with Crohn’s disease (CD) and how regional differences in treatment strategies impact the disease course. Methods Patients were followed prospectively from the time of diagnosis, with uniform collection data. Associations between outcomes and covariates were analyzed by multivariable Cox regressions in a propensity score-matched sub-population to address time to first intestinal resection. Results A total of 547 patients with CD were recruited (Eastern Europe: 139 [25.4%]; Western Europe: 408 [74.6%]). Ten-year cumulative rate of advanced therapy use was higher in Western (42%) compared with Eastern Europe (27%) ( P < .05). The median period until initiation of advanced treatment was shorter in Western Europe (10 vs 46 months; P < .001). Despite these differences, the need for surgery remained comparable in Eastern and Western Europe, with a 10-year rate of 24% ( P = .9). A similar comparability was observed for disease progression from uncomplicated disease to complicated disease (10-year rate: 20%; P = .07) and hospitalization (10-year rate: 41%; P = .5). Use of advanced therapy, stricturing or penetrating disease at diagnosis, progression of disease behavior, and former smoking were all associated with an increased risk of intestinal resection (all P < .05). Conclusions Despite earlier and more frequent use of advanced therapies in Western Europe, no differences in disease outcomes were observed between Western and Eastern European patients. Ten years after diagnosis, 1 in 5 patients with uncomplicated disease at diagnosis progressed to complicated disease, and 1 in 4 needed surgery.
KW - Crohn’s disease
KW - Epidemiology
U2 - 10.1016/j.cgh.2025.10.022
DO - 10.1016/j.cgh.2025.10.022
M3 - Journal article
C2 - 41192804
AN - SCOPUS:105025117025
SN - 1542-3565
VL - 24
SP - 1675
EP - 1687
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 6
ER -